癌症研究
肾透明细胞癌
血管生成
缺氧诱导因子
免疫疗法
细胞生长
肾细胞癌
HIF1A型
抑制器
细胞
缺氧(环境)
生物
癌症
医学
化学
肿瘤科
内科学
基因
有机化学
生物化学
氧气
遗传学
作者
Olga Martínez-Sáez,P. Gajate Borau,Teresa Alonso‐Gordoa,Javier Molina‐Cerrillo,Enrique Grande
标识
DOI:10.1016/j.critrevonc.2017.01.013
摘要
The loss of the Von Hippel-Lindau tumor suppressor (VHL) is a key oncogenic event in the vast majority of patients with clear cell renal cell carcinoma (ccRCC). With the loss of the VHL protein (pVHL) function, the hypoxia inducible factor α (HIF-α) accumulates inside the tumor cell and dimerizes with HIF-β. The HIF-α/HIF-β complex transcriptionally activates hundreds of genes promoting the adaptation to hypoxia that is implicated in tumor development. There is growing evidence showing that HIF-2α subunit has a central role in ccRCC over HIF-1α. Thus, efforts have been made to specifically target this pathway. PT2385 and PT2399 are first-in-class, orally available, small molecule inhibitors of HIF-2 that selectively disrupt the heterodimerization of HIF-2α with HIF-1β. Preclinical and clinical data indicate that these new molecules are effective in blocking cancer cell growth, proliferation, and tumor angiogenesis characteristic in ccRCC. Treatment with HIF-2α specific antagonists, either alone or in combination with immunotherapy or other antiangiogenic agents have the potential to transform the therapeutic landscape in this tumor in the future. Herein, we summarize the molecular background behind the use of HIF-2α inhibitors in ccRCC and give an overview of the development of new agents in this setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI